A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis
- PMID: 1570496
- DOI: 10.3109/03009749209095074
A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis
Abstract
This double-blind, parallel group study was conducted to evaluate the gastroduodenal safety and antiarthritic efficacy of a fixed combination of diclofenac sodium 50 mg and misoprostol 200 mcg, compared with a combination of diclofenac 50 mg and placebo. Three hundred and thirty-nine patients with rheumatoid arthritis and no significant gastric or duodenal mucosal damage were enrolled and received study medication (diclofenac/misoprostol, 164; diclofenac/placebo, 175) BID or TID for 12 weeks. Posttreatment gastroduodenal endoscopic examinations revealed ulcers in 11% of the diclofenac/placebo group, compared with only 4% of the diclofenac/misoprostol group (p = 0.034). Four-weekly assessments of arthritic condition revealed no clinically or statistically significant treatment differences. It was concluded that diclofenac/misoprostol caused significantly less gastroduodenal damage than diclofenac, but was as effective as diclofenac alone in the treatment of rheumatoid arthritis.
Similar articles
-
Double-blind comparison of the efficacy of diclofenac/misoprostol and diclofenac in the treatment of rheumatoid arthritis.Eur J Rheumatol Inflamm. 1994;14(2):5-13. Eur J Rheumatol Inflamm. 1994. PMID: 7744133 Clinical Trial.
-
Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients.Am J Gastroenterol. 1997 Apr;92(4):663-7. Am J Gastroenterol. 1997. PMID: 9128319 Clinical Trial.
-
The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis.Br J Rheumatol. 1992 Nov;31(11):753-8. doi: 10.1093/rheumatology/31.11.753. Br J Rheumatol. 1992. PMID: 1450797 Clinical Trial.
-
Efficacy and gastroduodenal safety of a fixed combination of diclofenac and misoprostol in the treatment of arthritis.Br J Rheumatol. 1995 Apr;34 Suppl 1:11-8. doi: 10.1093/rheumatology/xxxiv.suppl_1.11. Br J Rheumatol. 1995. PMID: 7780674 Review.
-
Arthrotec: a therapeutic option in the management of arthritis.Eur J Rheumatol Inflamm. 1993;13(1):25-32. Eur J Rheumatol Inflamm. 1993. PMID: 7821336 Review.
Cited by
-
Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition.Gut Liver. 2020 Nov 15;14(6):707-726. doi: 10.5009/gnl20246. Gut Liver. 2020. PMID: 33191311 Free PMC article. Review.
-
Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses.Open Access Rheumatol. 2013 Feb 26;5:1-19. doi: 10.2147/OARRR.S41420. eCollection 2013. Open Access Rheumatol. 2013. PMID: 27790020 Free PMC article.
-
Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.Cardiovasc Ther. 2016 Apr;34(2):59-66. doi: 10.1111/1755-5922.12172. Cardiovasc Ther. 2016. PMID: 26725920 Free PMC article. Clinical Trial.
-
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.Drug Healthc Patient Saf. 2009;1:47-71. doi: 10.2147/dhps.s4334. Epub 2009 Oct 28. Drug Healthc Patient Saf. 2009. PMID: 21701610 Free PMC article.
-
[Mucosa protective therapy with long-term nonsteroidal antirheumatic drugs].Wien Med Wochenschr. 2003;153(13-14):295-303. doi: 10.1046/j.1563-258x.2003.03035.x. Wien Med Wochenschr. 2003. PMID: 12924104 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical